142 related articles for article (PubMed ID: 36031684)
1. Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod.
Morillos MB; de Aguiar PHP; Franceschini PR; Duarte JÁ; Piccini CD; Finkelsztejn A
Neurol Sci; 2023 Jan; 44(1):361-363. PubMed ID: 36031684
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.
Manouchehri N; Mirmosayyeb O; Badihian S; Shaygannejad V
Mult Scler Relat Disord; 2018 Jan; 19():121-123. PubMed ID: 29195114
[TBL] [Abstract][Full Text] [Related]
3. A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.
Stitt DW; Boes CJ; Flanagan EP; Howard MT; Colgan JP
Mult Scler Relat Disord; 2018 Jan; 19():115-117. PubMed ID: 29190574
[TBL] [Abstract][Full Text] [Related]
4. Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
Papathemeli D; Gräfe R; Hildebrandt U; Zettl UK; Ulrich J
Mult Scler; 2016 Dec; 22(14):1888-1890. PubMed ID: 27207455
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
Fragoso YD
Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
[TBL] [Abstract][Full Text] [Related]
6. Listeria monocytogenes rhombencephalitis in a patient with multiple sclerosis during fingolimod therapy.
Tecellioglu M; Kamisli O; Kamisli S; Erdogmus UA; Özcan C
Mult Scler Relat Disord; 2019 Jan; 27():409-411. PubMed ID: 30530070
[TBL] [Abstract][Full Text] [Related]
7. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
[TBL] [Abstract][Full Text] [Related]
8. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
9. Peripheral T-cell lymphomas as fingolimod-associated lymphoproliferative disorder for patients with multiple sclerosis - case report with literature review.
Kawai H; Matsushita H; Akashi H; Furuya D; Kawakami S; Suzuki R; Moriuchi M; Ogawa Y; Kawada H; Nakamura N; Ando K
Leuk Lymphoma; 2020 Apr; 61(4):959-962. PubMed ID: 31773997
[No Abstract] [Full Text] [Related]
10. Autoimmune hemolytic anemia after treatment with fingolimod in a patient with multiple sclerosis (MS): A case report and review of the literature.
Najdaghi S; Davani DN; Ghajarzadeh M; Shaygannejad V
Autoimmun Rev; 2022 Dec; 21(12):103203. PubMed ID: 36220524
[No Abstract] [Full Text] [Related]
11. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
[TBL] [Abstract][Full Text] [Related]
12. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
Samaraweera AP; Cohen SN; Akay EM; Evangelou N
Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
[TBL] [Abstract][Full Text] [Related]
13. Soft Palate Malignant Melanoma as an Adverse Effect of Fingolimod in Multiple Sclerosis: A Case Report and Literature Review.
Mozhdehipanah H; Safdarian F; Paybast S
Neurol India; 2023; 71(3):546-548. PubMed ID: 37322755
[TBL] [Abstract][Full Text] [Related]
14. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.
Evangelopoulos ME; Miclea A; Schrewe L; Briner M; Salmen A; Engelhardt B; Huwiler A; Chan A; Hoepner R
CNS Neurosci Ther; 2018 Oct; 24(10):984-986. PubMed ID: 29898493
[No Abstract] [Full Text] [Related]
15. Fingolimod (Gilenya) and melanoma.
Robinson CL; Guo M
BMJ Case Rep; 2016 Dec; 2016():. PubMed ID: 28003234
[TBL] [Abstract][Full Text] [Related]
16. Cerebral toxoplasmosis in an MS patient receiving Fingolimod.
Enriquez-Marulanda A; Valderrama-Chaparro J; Parrado L; Diego Vélez J; Maria Granados A; Luis Orozco J; Quiñones J
Mult Scler Relat Disord; 2017 Nov; 18():106-108. PubMed ID: 29141790
[TBL] [Abstract][Full Text] [Related]
17. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
Christopher KL; Elner VM; Demirci H
Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
[TBL] [Abstract][Full Text] [Related]
18. Neurodevelopmental retardation in a baby born to a multiple sclerosis patient being treated with fingolimod.
Cheraghmakani H; Nasehi MM; Baghbanian SM
Mult Scler Relat Disord; 2019 Aug; 33():116-120. PubMed ID: 31185372
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis.
Cuascut FX; Alkabie S; Hutton GJ
Mult Scler Relat Disord; 2021 Aug; 53():103072. PubMed ID: 34139459
[TBL] [Abstract][Full Text] [Related]
20. Fingolimod-Associated Intracerebral Lymphoproliferative Disorder.
Baharnoori M; Mahajan R; Solomon IH; Pinkus G; Houtchens M
Am J Ther; 2019; 26(4):e481-e484. PubMed ID: 29189316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
